打开APP

TransCelerate BioPharma促使大型药企间达成研究用药供应协议

  1. TransCelerate BioPharma
  2. 研究用药
  3. 药物开发

来源:生物谷 2013-08-26 09:17

2013年8月25日讯 /生物谷BIOON/ --不久前,美国的医药行业联盟TransCelerate BioPharma发起了一项关于保证医药企业研发用药的正常供应的协议。在过去的几年中,医药企业的新药研发者经常为无法及时购买到相应的竞争药物做参照而头疼。这一现象在癌症治疗药物研发中尤为突出(因为没有企业愿意主动帮助自己产品的竞争者)。这也造成了药物研发工作经常无法按计划完成。

2013年8月25日讯 /生物谷BIOON/ --不久前,美国的医药行业联盟TransCelerate BioPharma发起了一项关于保证医药企业研发用药的正常供应的协议。在过去的几年中,医药企业的新药研发者经常为无法及时购买到相应的竞争药物做参照而头疼。这一现象在癌症治疗药物研发中尤为突出(因为没有企业愿意主动帮助自己产品的竞争者)。这也造成了药物研发工作经常无法按计划完成。现在,在TransCelerate BioPharma牵头下,强生、罗氏、辉瑞等几大制药巨头加入了一项保证药物研发用药正常供应的协议。今后研究人员将不用再求助于经销商来购得其所需要的药物,而是可以直接从相应的公司来直接获得,从而将大大加快研究进度。(生物谷Bioon.com)

详细英文报道:

Just days ago the pharma industry consortium TransCelerate BioPharma flagged the completion of its "comparator network," a new initiative aimed at ensuring that developers out to go head-to-head with an approved drug in a clinical study will have a secure supply of the comparator drug as needed.

Over the past two years investigators have been bedeviled by irregular supplies of the drugs--particularly cancer drugs--they're going up against. A host of supply shortages was making it difficult and sometimes impossible to complete a study on schedule. And the new network obtained pledges from members, which includes heavyweights like Roche ($RHHBY), Johnson & Johnson ($JNJ) and Pfizer ($PFE), that they could make that problem go away.

This new industry agreement should also help resolve shortages that can result from a sudden demand for drugs needed for clinical trials--a situation likely to become more common as more specialized therapies make it to the market.

"When a buying company is looking to buy a comparator drug product for a clinical trial, it often ends up buying all of the product they need from a wholesaler, who in turn will buy the product in a smaller region or country of the world," says a spokesperson for TransCelerate. This can cause stock outs and drug shortages.

"With the activation of our Comparator Network the participating TransCelerate companies will be able to source these comparator drugs directly from each other, be able to secure supply when they need it in the quantities they need, have access to drug data and totally mitigate the risk of counterfeit drugs in that clinical trial," said CEO Dalvir Gill in a statement.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->